Online citations, reference lists, and bibliographies.

Availability And Approval Of Cannabis‐based Medicines For Chronic Pain Management And Palliative/supportive Care In Europe: A Survey Of The Status In The Chapters Of The European Pain Federation

Nevenka Krčevski-Škvarč, Christine Wells, Winfred Häuser
Published 2018 · Medicine
Cite This
Download PDF
Analyze on Scholarcy
Share
BACKGROUND There is considerable public and political interest in the use of cannabis products for medical purposes. METHODS The task force of the European Pain Federation (EFIC) conducted a survey with its national chapters representatives on the status of approval of all types of cannabis-based medicines, the covering of costs and the availability of a position paper of a national medical association on the use of medical cannabis for chronic pain and for symptom control in palliative/supportive care. RESULTS Thirty-one out of 37 contacted councillors responded. Plant-derived tetrahydrocannabinol/cannabidiol (THC/CBD) oromucosal spray is approved for spasticity in multiple sclerosis refractory to conventional treatment in 21 EFIC chapters. Plant-derived THC (dronabinol) is approved for some palliative care conditions in four EFIC chapters. Synthetic THC analogue (nabilone) is approved for chemotherapy-associated nausea and vomiting refractory to conventional treatment in four EFIC chapters'. Eight EFIC chapters' countries have an exceptional and six chapters an expanded access programme for medical cannabis. German and Israeli pain societies recommend the use of cannabis-based medicines as third-line drug therapies for chronic pain within a multicomponent approach. Conversely, the German medical association and a team of finish experts and officials do not recommend the prescription of medical cannabis due to the lack of high-quality evidence of efficacy and the potential harms. CONCLUSIONS There are marked differences between the countries represented in EFIC in the approval and availability of cannabis-based products for medical use. EFIC countries are encouraged to collaborate with the European Medicines Agency to publish a common document on cannabis-based medicines. SIGNIFICANCE There are striking differences between European countries in the availability of plant-derived and synthetic cannabinoids and of medical cannabis for pain management and for symptom control in palliative care and in the covering of costs by health insurance companies or state social security systems.
This paper references
10.1016/j.drugalcdep.2015.11.015
Trends in registered medical marijuana participation across 13 US states and District of Columbia.
Brian J Fairman (2016)
10.1016/j.jpain.2015.07.014
Cannabis for the Management of Pain: Assessment of Safety Study (COMPASS).
Mark A. Ware (2015)
10.1159/000444236
Health Authorities Data Collection of THC:CBD Oromucosal Spray (L'Agenzia Italiana del Farmaco Web Registry): Figures after 1.5 Years
Francesco Patti (2016)
10.1186/s12954-016-0129-7
Irish general practitioner attitudes toward decriminalisation and medical use of cannabis: results from a national survey
Des Crowley (2017)
Medical use of cannabis products : Lessons to be learned from Israel and Canada
J. N. Ablin
10.1056/NEJMra1402309
Adverse health effects of marijuana use.
Nora D. Volkow (2014)
10.1002/ejp.1118
Efficacy, tolerability and safety of cannabis‐based medicines for chronic pain management – An overview of systematic reviews
Winfred Häuser (2018)
10.5041/RMMJ.10239
Attitudes of Israeli Rheumatologists to the Use of Medical Cannabis as Therapy for Rheumatic Disorders
Jacob N Ablin (2016)
10.1007/s00482-015-0089-y
[Efficacy, tolerability and safety of cannabinoids for chronic neuropathic pain: A systematic review of randomized controlled studies].
Frank Petzke (2016)
10.1186/1471-2474-15-258
Rheumatologists lack confidence in their knowledge of cannabinoids pertaining to the management of rheumatic complaints
Mary-Ann Fitzcharles (2014)
Kannabistako kipul€ a€ akkeksi? Suomen L€ a€ ak€ arilehti 71
E Kalso (2016)
Medical cannabis . Number of applications increases [ German ]
K. Gießelmann (2017)
Guideline on clinical medicinal products intended for the treatment of neuropathic pain
European Medicines Agency (2007)
Main principles of Cannabis policy for medical use
Ministry of Health (2016)
10.1503/cmaj.109-5129
Growing the evidence base for medical cannabis
Shannon Lough (2015)
10.1016/j.annemergmed.2019.07.034
[MEDICAL CANNABIS].
Timna Naftali (2016)
10.1007/s00482-015-0083-4
Medical use of cannabis products
Jacob Ablin (2015)
Medical cannabis Physicians against cannabis flowers
P B€ Uhring (2016)
10.1097/AJP.0000000000000364
The Effect of Medicinal Cannabis on Pain and Quality-of-Life Outcomes in Chronic Pain: A Prospective Open-label Study.
Simon Haroutounian (2016)
10.15252/embr.201439742
Medicinal use of cannabis in Europe: the fact that more countries legalize the medicinal use of cannabis should not become an argument for unfettered and uncontrolled use.
Maurizio Bifulco (2015)
Cannabis for medical use: a scientific review.
Lucy Dillon (2017)
Medical cannabis. German Pain Society welcomes the enactment of the federal government
Cannabis for medical use
Health Products Regulatory Agency (2017)
10.1007/s11926-016-0625-5
Cannabinoids in the Management of Musculoskeletal or Rheumatic Diseases
Mary-Ann Fitzcharles (2016)



This paper is referenced by
10.1007/s00482-019-00397-1
Cannabispräparate für die Therapie chronischer Schmerzen
Marc Heidbreder (2019)
10.1080/1744666X.2019.1665997
Medical cannabis and cannabinoids in rheumatology: where are we now?
Piercarlo Sarzi-Puttini (2019)
10.18004/rvspmi/2312-3893/2018.05(02)12-018
Cannabis in chronic pain - An indication supported by scientific evidence?
Manuel Benítez Codas (2018)
10.1007/s11469-019-00152-8
Medical Cannabis Pain Benefit, Risk and Effectiveness Perceptions Among Belarus Medical Students
Natallia Khamenka (2019)
10.1007/s00482-019-0383-1
[Cannabis-based medicines for chronic pain: indications, selection of drugs, effectiveness and safety : Experiences of pain physicians in Saarland].
Patric Bialas (2019)
10.1016/j.bcp.2018.07.033
Chronic pain and cannabinoids. Great expectations or a christmas carol
Diego Pascual (2018)
10.1007/s00406-018-0960-9
Understanding the evidence for medical cannabis and cannabis-based medicines for the treatment of chronic non-cancer pain
Gabrielle Campbell (2018)
10.1016/j.euroneuro.2020.04.009
Experiences with medical cannabis in the treatment of veterans with PTSD: Results from a focus group discussion
Erwin Krediet (2020)
10.15416/pcpr.v3i3.19979
Should Cannabis as Medicine be Specifically Regulated
Gunawan Widjaja (2018)
10.1007/s00482-019-0383-1
Cannabispräparate bei chronischen Schmerzen: Indikationen, Präparateauswahl, Wirksamkeit und Sicherheit
Patric Bialas (2019)
10.14740/jocmr4210
A Scoping Review on Clinical Trials of Pain Reduction With Cannabis Administration in Adults
Reham Haleem (2020)
10.1002/ejp.1297
European Pain Federation (EFIC) position paper on appropriate use of cannabis‐based medicines and medical cannabis for chronic pain management
Winfried Häuser (2018)
10.1007/s00482-019-00407-2
Ein Positionspapier zu medizinischem Cannabis und cannabisbasierten Medikamenten in der Schmerzmedizin
Frank Petzke (2019)
10.1016/j.bmcl.2019.03.013
Analyzing the role of cannabinoids as modulators of Wnt/β-catenin signaling pathway for their use in the management of neuropathic pain.
Yedukondalu Nalli (2019)
10.1136/rapm-2020-101521
Daring discourse – yes: practical considerations for cannabis use in the perioperative setting
Hance Clarke (2020)
10.1007/s00482-019-00409-0
Medizinalcannabis und cannabisbasierte Arzneimittel: ein Appell an Ärzte, Journalisten, Krankenkassen und Politiker für einen verantwortungsvollen Umgang
Winfried Häuser (2019)
10.1007/s00482-019-0373-3
Efficacy, tolerability and safety of cannabis-based medicines for cancer pain
Winfried Häuser (2019)
10.1007/s40674-019-00130-0
Cannabis-Based Medicines and Medical Cannabis in Rheumatic Diseases: A Treasure Chest or Pandora’s box
Mary-Ann Fitzcharles (2019)
10.1186/s13741-019-0127-x
Cannabis-based medicines and the perioperative physician
Patrick Tapley (2019)
10.3390/ijerph16173095
International Perspectives on the Implications of Cannabis Legalization: A Systematic Review & Thematic Analysis
Anees Bahji (2019)
10.1007/s00482-019-00403-6
Erratum zu: Cannabispräparate bei chronischen Schmerzen: Indikationen, Präparateauswahl, Wirksamkeit und Sicherheit
Patric Bialas (2019)
10.1007/978-3-319-90365-1_6
The Molecular Basis of Cannabinoid Activity: Application to Therapeutics Design and Discovery for Cannabis Use Disorders
David R Janero (2019)
10.3389/fneur.2018.00731
Cannabidiol for Treatment of Childhood Epilepsy–A Cross-Sectional Survey
Kerstin Alexandra Klotz (2018)
10.1016/j.jns.2020.116717
Clinical uses of cannabis and cannabinoids in the United States
Erik A. Levinsohn (2020)
10.3390/cancers11020129
Prospects for the Use of Cannabinoids in Oncology and Palliative Care Practice: A Review of the Evidence
Tomasz Dzierżanowski (2019)
Ad-hoc-Kommission der Deutschen Schmerzgesellschaft „ Cannabis in der Medizin “ · Matthias Karst
Knud Gastmeier (2019)
10.1007/s11481-020-09905-y
Analgesic Effects of Cannabinoids for Chronic Non-cancer Pain: a Systematic Review and Meta-Analysis with Meta-Regression
Stanley S. Wong (2020)
10.1016/J.RHUM.2019.03.009
Le cannabis dans les douleurs musculosquelettiques et articulaires : des preuves sont nécessaires
Serge Perrot (2019)
10.1007/s00103-019-02966-2
Evidenz der Wirksamkeit und Sicherheit von Cannabispräparaten bei chronischen Schmerzen
Winfried Häuser (2019)
10.1002/acr2.11138
Medical Cannabis Use by Rheumatology Patients Following Recreational Legalization: A Prospective Observational Study of 1000 Patients in Canada
Mary-Ann Fitzcharles (2020)
10.1002/14651858.CD012182.pub2
Cannabis-based medicines for chronic neuropathic pain in adults.
Martin Muecke (2018)
Semantic Scholar Logo Some data provided by SemanticScholar